1 / 13

MLAB 1415- Hematology Keri Brophy-Martinez

MLAB 1415- Hematology Keri Brophy-Martinez. Chapter 23: Myelodysplastic Syndromes. MYELODYSPLASTIC SYNDROMES.

tarak
Télécharger la présentation

MLAB 1415- Hematology Keri Brophy-Martinez

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MLAB 1415- HematologyKeri Brophy-Martinez Chapter 23: Myelodysplastic Syndromes

  2. MYELODYSPLASTIC SYNDROMES • A group of acquired clonal hematologic disorders characterized by progressive cytopenias in the peripheral blood, reflecting defects in erythroid, myeloid and/or megakaryocytic maturation. • Bone marrow is hyperplastic • The result in impaired hematopoiesis. • The origin is currently unknown. • Affects people over 50 with a slight male predominance

  3. Terms used to describe MDS • Preleukemic leukemia or syndrome • Preleukemic acute human leukemia • Chronic refractory anemia with sideroblasts • Smoldering leukemia

  4. Risk factors • Age • Genetic predisposition • Chromosomes 5,7 and 8 • Down’s, Fanconi’s • Environmental exposures • benzene • Prior therapy • Radiation • Chemotherapy

  5. Clinical findings • Symptoms are related to progressive bone marrow failure • Infections • Bleeding • Weight loss • Cardiovascular • Death usually occurs from infection and/or bleeding or from leukemia if transformation occurs.

  6. Hematologic abnormalities in MDS

  7. Dysgranulopoiesis

  8. FAB classification • Five MDS subtypes: • Refractory anemia (RA) • Refractory anemia with ringed sideroblasts (RARS) • Refractory anemia with excess blasts (RAEB) • Refractory anemia with excess blasts in transformation (RAEB-t) • Chronic myelomonocytic leukemia (CMML)

  9. WHO classification • Refractory anemia (RA) • Anemia is primary finding, but unresponsive to treatment • Refractory anemia with ringed sideroblasts (RARS) • >15% ringed sideroblasts in bone marrow • Refractory cytopenia with multilineage dysplasia (RCMD) • Dysplastic features in at least 10% of cells in two or more lines • RA with excess blasts-1 (RAEB) Cytopenia in at least two lineages, with qualitative abnormalities in all three cell lines

  10. MDS/MPD Diseases • Clonal hematopoietic neoplasms that at initial presentation have some clinical, laboratory or morphological findings of both a MDS/MPD • Abnormalities in the regulation of myeloid proliferation, maturation and cell survival • Diseases • CMML associated with persistent monocytosis • Others

  11. Chronic Myelomonocytic Leukemia (CMML) • Monocytosis • ↑ in mature monocytes (some forms have ↑ monoblasts and promonocytes) • Bone marrow hypercellular • Splenomegaly and hepatomegaly (in patients with high WBC count)

  12. Therapy • Currently, there is no really good treatment for MDS, therefore most therapy is supportive, such as transfusion of blood components and antibiotics. • Treatments that modulate the immune system, such as steroids and interferon have been used to some success. • The only effective treatment is bone marrow transplant, but most patients are too old to survive the rigors of this treatment.

  13. References • McKenzie, Shirlyn B., and J. Lynne. Williams. "Chapter 21." Introduction. Clinical Laboratory Hematology. Boston: Pearson, 2010. Print

More Related